See how researchers at
St. Jude Children’s Research Hospital used cryo-electron microscopy to solve structures of the LRRK2/Rab29 complex, showing potential routes for drug treatment against Parkinson’s disease
St. Jude researcher Madan Babu with Brian Kobilka, Michel Bouvier, and Franziska Heidenreich probe the individual contribution of each amino acid in G-protein coupled receptor which binds adrenaline to expand understanding of top drug target
Learn how scientists at
St. Jude gained new understanding of the genomic events that predispose children to bilateral Wilms tumor, cancer in both kidneys.
Childhood cancer survivors have a higher prevalence of prediabetes & diabetes than peers. Learn how treating these conditions may protect heart & kidney health.
James R. Downing, MD, listed as one of 100 influential people in healthcare in 2023.
Adding a modular chimeric cytokine receptor to CAR T cells increased their efficacy. Learn how this modular system could improve brain and solid tumor therapy.
St. Jude scientists identified 229 genes regulated by undruggable oncogenic HOXA9. Learn how it may lead to better treatments for high risk pediatric leukemias.
GRP78 is a promising CAR T-cell immunotherapy target for brain and solid tumors. Discover why it’s special, including how cancer uses it to trick immune cells.
Find how mapping chromatin accessibility & regulation in pediatric acute lymphoblastic leukemia (ALL) subtypes may uncover therapy response heterogeneity cause.
Discover how T-cell differentiation nodes can be promoted or blocked to improve immunotherapy anticancer efficacy according to new T-cell exhaustion research.
Fusion positive pediatric rhabdomyosarcoma (RBD) can come from non-muscle cells with a fusion oncoprotein. Find how the
St. Jude discovery may change treatment.
Learn more about the
St. Jude scientists who are among the most highly cited researchers in the world, a distinction that reflects the value of their work among other investigators.
Dr. Robinson is now also co-leader of the Neurobiology and Brain Tumor Program in the
St. Jude Comprehensive Cancer Center.
See how researchers at
St. Jude Children’s Research Hospital used cryo-electron microscopy to solve structures of a neurotransmitter (dopamine, serotonin) transporter VMAT2 responsible for packing vesicles in neurons for signaling.
The boards of
St. Jude and ALSAC have new chairs and vice-chairs who will oversee the bold commitments of the ongoing strategic plan.
Lentiviral gene therapy for X-linked severe combined immunodeficiency disorder (SCID-X1) is safe. Discover how 3D DNA structure explains biology & safety.
Childhood cancer survivors are at higher risk for second cancer & associated mortality. Find how genetic variants increase risk & can be used to protect health.
See how machine learning was used to gain insight into condensation behavior and oncogenic mechanisms of fusion oncoproteins.
St. Jude partners with Domino's to build a six-story building for patients and families. The multimillion-dollar housing facility is part of Domino's 10-year commitment to
Hyperdiploid B-cell acute lymphoblastic leukemia has evaded a consensus definition. Find the definitions that best correlated with better patient outcomes.
T cells can slow Alzheimer’s disease progression in a model system. Find how the neuro-immune study may be the future of neurodegenerative disease research.
St. Jude has announced funding for employee-generated ideas. Find out about the approved projects
See how one protein responsible for chemotherapy resistance functions and how we can prevent future drug resistance to improve treatment
Who will get sick from influenza infection has long been a mystery. Learn how immune cells may predict susceptibility to symptoms long before flu infection.
Award-winning NICU expert spent 21 years at Children’s Wisconsin, 4 years as executive director of perinatal/ neonatal services.
See how a new model developed by
St. Jude scientists looking at influenza evolution can predict future virus mutations.
Zhang is one of 15 other scientists being honored by ISCB in 2023.
Learn how Pediatric Early Warning Systems save the lives of children with cancer in Latin America by identifying early when they are in need of supportive care.
See how creating a new research model to study hepatoblastoma (liver cancer) gave
St. Jude scientists clues into potential therapeutic targets
Cancer cells & the immune cells that activate the anti-cancer response compete over the nutrient glutamine. Discover how it may improve cancer therapies.
Adenosine base editing restarted fetal hemoglobin expression in cells from patients with sickle cell disease. Find how
St. Jude & Broad are advancing to a cure.
The U.S. News Best Children’s Hospitals for Cancer rankings rely on clinical data and on an annual survey of pediatric specialists.
He is being recognized by the American Statistical Association for his leadership role in numerous
St. Jude survivorship studies.
Dr. Victor J. Torres is leading a newly-formed department called the
St. Jude Department of Host-Microbe Interactions, which will focus on treating and preventing disease-causing infections in children.
$9 million initiative addresses shortage of top young scientists entering pediatric cancer research careers.
NLRP12 bridges hemolysis, inflammation and multi-organ damage. Learn how this ‘on’ switch for innate immune cell death could be a drug target to prevent pathology.
Find how H5N1 avian influenza viruses increased disease-causing abilities & gained the capability to enter mammalian brains as they spread west across North America.
Read about how Scientists at
St. Jude determined how the SWI/SNF chromatin remodeling complex helps cancer cells remember how to be cancerous after division.
St. Jude scientists are studying how pioneer transcription factors access tightly wound DNA. Learn about how their findings may impact therapeutic development.
St. Jude scientists captured six new structures of the Spns2 transporter, providing insights to aid therapeutic design for cancer and other diseases.
Director of the
St. Jude Center of Excellence for Data-Driven Discovery named a fellow of the 360-year-old British scientific organization.
NetBID2 finds hidden drivers by extracting more from multi-omics data. Learn how the computational tool can find druggable targets in cancer and other diseases.
Find how the neighborhood economic hardship index predicts baseline and long-term outcomes in pediatric brain tumor patients treated with radiation therapy.
Proton therapy for craniopharyngioma had better neurocognitive than & similar survival outcomes as historical photon therapy. Read the phase 2 clinical trial.
Genomic prime editing, a new DNA-changing technology, fixed sickle cell disease mutations in patient cells. Learn how it could lead to cure for genetic anemias.
St. Jude investigators will receive awards at the 2023 AACR meeting. Learn about their careers & the science they & their
St. Jude peers will be sharing.
St. Jude scientists found that combination of BET and GSK3 inhibitors can overcome treatment resistance in a type of childhood leukemia. Read about the study.
A report from the Childhood Cancer Survivor Study (CCSS) provides strong evidence of the importance of a healthy lifestyle for adults who were treated for cancer as children
St. Jude scientists found that human ribosomes decode mRNA slower but more accurately than bacteria. Read about the study’s implications for drug development.
St. Jude research cataloguing the oncogenic fusions in pediatric acute myeloid leukemia (AML) could lead to cures using genome editing (CRISPR-Cas9).
National leader in the field of childhood cancer survivorship will spearhead research and advancements.
Influenza (flu) vaccines and pandemic predictions can be improved; learn how
St. Jude scientists found impactful hemagglutinin mutations contributing to both.
Learn about how the cystic fibrosis transmembrane conductance regulator works and how findings from
St. Jude will help therapeutic development.
The renamed department will investigate the biological mechanisms underlying the effects of catastrophic disease on the brain.
St. Jude scientists overcame drug resistance and drug toxicity, using X-ray crystallography to avoid the detoxification pregnane X receptor (PXR).
Internationally renowned expert will focus on growing
St. Jude into a global leader in infectious diseases research.
This free online resource of information and education for families facing childhood and adolescent cancer has a truly global reach.
Find out how Scientists at
St. Jude solved the 3D structure of a cellular train in cilia, IFT-A, at nearly ten times the resolution of previous efforts.
Find how increased mortality in childhood cancer survivors is independently associated with local resource deprivation and certain chronic health conditions.
Explore how deep sequencing childhood cancer survivors found the mutational fingerprint of a toxic chemotherapy associated with a marker of accelerated aging.
Discover how chimeric antigen receptors (CARs) with a new anchor domain increased anti-cancer activity of cellular immunotherapies in cancer models.
Immunologist recognized for her achievements in innate immunity, developing new concepts in inflammasome biology, inflammatory cell death.
Expert in human-centered design to lead new
St. Jude department focused on advancing strategic plan.
Julie R. Park, M.D., to succeed longtime chair Ching-Hon Pui, M.D.
St. Jude used an innovative degradation system on CTCF, learning more about this protein’s role in transcription. Read about the findings.
Made possible by a $50 million donation from AbbVie, Family Commons is a space for patients and their families to relax and gather in between clinic appointments.
St. Jude scientists have captured the 3D structure of the SPOP protein, revealing how it contributes to cancer. Read about the implications for therapeutics.
St. Jude scientists performed the largest study yet examining drug sensitivity in childhood acute lymphoblastic leukemia across genomic subtypes and its association with treatment response.